Tech Company Financing Transactions
Senticell Funding Round
Senticell, based in Princeton, scored investment from National Institutes of Health.
Transaction Overview
Company Name
Announced On
9/29/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The funding will support preclinical and clinical work validating red blood cell-bound tumor DNA as an early detection biomarker for non-small cell lung cancer.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
150 Brooks Bend
Princeton, NJ 08540
USA
Princeton, NJ 08540
USA
Phone
Website
Email Address
Not Recorded
Overview
Senticell is a pioneering biotechnology and molecular diagnostics company developing a breakthrough platform that uses red blood cell (RBC) DNA and cfDNA analysis to revolutionize non-invasive disease detection. Our research demonstrates that RBCs act as immune-responsive biosensors, capable of carrying molecular and genetic biomarkers from across the body - unlocking a powerful and previously untapped gateway for liquid biopsy and precision diagnostics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Neha Shah
Chief Operating Officer
Mallik Srivatsan
Co-Founder
Nilam Mangalmurti
VP - Bus. Development
Kartik Shah
Browse more venture capital transactions:
Prev: 9/29/2026: Hertha Metals venture capital transaction
Next: 9/29/2026: Metallus venture capital transaction
Share this article
Where The Data Comes From
We do our best to record funding rounds that are announced publicly. VC investment data records reported here come from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs